Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes

Table 1 Baseline demographics, mean ± SD/n (%)

Variables	Total (n = 1310)	Screening (n = 264)	Validation (n = 1046)	P value
MASLD	577 (44.0)	133 (50.4)	444 (42.4)
Age (years)	48.6 ± 13.1	47.8 ± 12.3	48.8 ± 13.3	0.238
Sex (male)	617 (47.2)	157 (59.5)	460 (44.1)	8.4 × 10-6
Body mass index (kg/m2)	24.5 ± 3.8	24.3 ± 3.9	24.5 ± 3.8	0.545
Waist circumference (cm)	81.6 ± 10.5	83.2 ± 11.2	81.2 ± 10.2	0.017
Hip circumference (cm)	96.2 ± 7.4	96.5 ± 7.7	96.1 ± 7.4	0.483
Fasting glucose (mg/dL)	95.1 ± 29.4	98.1 ± 26.9	94.3 ± 30.0	0.063
Cholesterol (mg/dL)	196.7 ± 38.6	185.5 ± 31.3	199.5 ± 39.7	1.6 × 10-9
Triglyceride (mg/dL)	130.8 ± 97.1	127.4 ± 77.3	131.6 ± 101.5	0.530
High density lipoprotein (mg/dL)	56.7 ± 14.2	55.4 ± 13.1	57.0 ± 14.5	0.086
Low density lipoprotein (mg/dL)	126.1 ± 35.6	125.0 ± 35.1	126.4 ± 35.7	0.569
AST ULN ratio	0.58 ± 0.29	0.73 ± 0.27	0.54 ± 0.28	1.1 × 10-22
ALT ULN ratio	0.58 ± 0.41	0.73 ± 0.52	0.55 ± 0.37	9.0 × 10-8
Diabetes mellitus	74 (5.8)	18 (6.9)	56 (5.6)	0.410
Hypertension	213 (16.7)	42 (16.2)	171 (16.9)	0.798
Hyperlipidemia	142 (12.0)	34 (13.4)	108 (11.7)	0.455

MASLD: Metabolic dysfunction-associated steatotic liver disease; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ULN: Upper limit of normal.